Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Vita Life SciencesASX:VLS +0.60%90 Net Cash per Share is A$0.17 as of Dec. 2025, which is 100% below its 10-year median of 20.51. GuruFocus rates ASX:VLS with a GF Score™ of 90/100 and a GF Value™ of A$2.49 (Fairly Valued). The stock has 1 warning sign investors should review. Among 257 Drug Manufacturers companies, Vita Life Sciences ranks worse than 66.93% on this metric.
The historical rank and industry rank for Vita Life Sciences's Net Cash per Share or its related term are showing as below:
ASX:VLS'
s Price-to-Net-Cash Range Over the Past 10 Years
Min: 3.63 Med: 20.51 Max: 135.5
Current: 14.91
During the past 13 years, the highest Price-to-Net-Cash Ratio of Vita Life Sciences was 135.50. The lowest was 3.63. And the median was 20.51.
ASX:VLS's Price-to-Net-Cash is ranked worse than 66.93% of 257
companies
in the Drug Manufacturers industry
Industry Median: 8.01
vs ASX:VLS: 14.91
Vita Life Sciences (ASX:VLS) Net Cash per Share Explanation
Ben Graham invested in situations where the company's stock price was lower than its net-cash. He assigned some value to the company's other current asset. The value is called Net Current Asset Value (NCAV). One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.
You can find companies that are traded below their Net Current Asset Value (NCAV) with our Net-Net screener.
Vita Life Sciences Net Cash per Share Related Terms
Vita Life Sciences Net Cash per Share Historical Data
* Premium members only.
The historical data trend for Vita Life Sciences's Net Cash per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:VLS vs ZTS, UTHR: Net Cash per Share Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Vita Life Sciences's Price-to-Net-Cash, along with its competitors' market caps and Price-to-Net-Cash data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vita Life Sciences Price-to-Net-Cash vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Vita Life Sciences's Price-to-Net-Cash distribution charts can be found below:
* The bar in red indicates where Vita Life Sciences's Price-to-Net-Cash falls into.
In the calculation of a company's Net Cash per Share, assets other than cash and short term investments are considered to be worth nothing. But the company has to pay its debt and other liabilities in full. This is an extremely conservative way of valuation. Most companies have negative Net Cash per Share. But sometimes a company's price may be lower than its net-cash.
Vita Life Sciences's Net Cash per Share for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vita Life Sciences (ASX:VLS) has a Net Cash per Share of A$0.17 as of Dec. 2025. Net cash per share equals the per-share value of cash and equivalents less total liabilities and minority interest. View historical data on Vita Life Sciences and its competitors. This is 99% below median its historical median of 20.51. Over the past decade, Vita Life Sciences' Net Cash per Share has ranged from 3.63 to 135.50. According to the industry distribution chart, Vita Life Sciences ranks #172 out of 257 companies in the Drug Manufacturers industry, placing it in the top 66.9%.
Is Vita Life Sciences' Net Cash per Share too high?
Vita Life Sciences' current Net Cash per Share of A$0.17 is 99% below median its 10-year median of 20.51. Over the past 10 years, this metric has ranged from a low of 3.63 to a high of 135.50. Based on the distribution chart, Vita Life Sciences ranks #172 out of 257 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Vita Life Sciences has a GF Score™ of 90/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Vita Life Sciences' Net Cash per Share compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Vita Life Sciences ranks #172 out of 257 companies for Net Cash per Share. This places Vita Life Sciences in the lower half of its industry. The industry median Net Cash per Share is 8.01. Historically, Vita Life Sciences' own Net Cash per Share has ranged from 3.63 to 135.50 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Cash per Share for a Drug Manufacturers company?
The median Net Cash per Share among Drug Manufacturers companies is 8.01, based on 257 companies in the industry. Companies in the top quartile (top 25%) have a Net Cash per Share significantly above this median, while those in the bottom quartile fall well below. However, Net Cash per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Cash per Share mean?
A high Net Cash per Share can signal that a stock is expensive relative to its fundamentals. Net cash per share equals the per-share value of cash and equivalents less total liabilities and minority interest. View historical data on Vita Life Sciences and its competitors. For the Drug Manufacturers industry, the median Net Cash per Share is 8.01 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vita Life Sciences's current Net Cash per Share is A$0.17, which is 99% below median its own 10-year median of 20.51. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vita Life Sciences stock overvalued right now?
Based on GuruFocus' analysis, Vita Life Sciences (ASX:VLS) is currently considered Fairly Valued. The stock's GF Value™ is A$2.49, compared to a current price of A$2.54 — trading 1.8% above its estimated fair value. The current Net Cash per Share is A$0.17, which is 99% below median its 10-year median of 20.51. Vita Life Sciences' overall GF Score™ is 90/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Cash per Share calculated?
Net Cash per Share is calculated from a company's financial statements. For Vita Life Sciences (ASX:VLS), the current Net Cash per Share is A$0.17 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vita Life Sciences (ASX:VLS) Overvalued in 2026?
Based on GuruFocus' analysis, Vita Life Sciences stock appears to be overvalued.
The current stock price of A$2.54 is trading 1.8% above its estimated GF Value™ of A$2.49.
GuruFocus considers Vita Life Sciences to be Fairly Valued.
Key valuation signals for ASX:VLS:
Net Cash per Share: A$0.17 (99% below median its 10-year median of 20.51)
GF Value™: A$2.49 vs. price of A$2.54 (1.8% above fair value)
No single metric tells the full story. See the ASX:VLS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vita Life Sciences Ltd is an Australian-based pharmaceutical and healthcare company involved in formulating, packaging, selling, and distributing vitamins and supplements. It produces a wide range of premium supplements, vitamins, minerals, herbs, and superfoods catered to all age categories and health conditions. The company markets its products through pharmacies and health food stores under the VitaHealth, VitaScience, and Herbs of Gold brands throughout the Asia-Pacific region. Vita Life Sciences has two operating segments: VMS Operational, which generates maximum revenue, and VMS Investments. Geographically, the Group generates maximum revenue from Malaysia and Singapore, and the rest from Australia, and China and Vietnam.
90GF Score
Get the complete analysis for ASX:VLS
Net Cash per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:VLS has been successfully added to your 
